Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]

BACKGROUND: Over 2021, COVID-19 vaccination programs worldwide focused on raising population immunity through the primary COVID-19 vaccine series. In Singapore, two mRNA vaccines (BNT162b2 and mRNA-1273) and the inactivated vaccine CoronaVac are currently authorized under the National Vaccination Pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Poh, Xuan Ying, Lee, I. Russel, Lim, Clarissa, Teo, Jefanie, Rao, Suma, Chia, Po Ying, Ong, Sean W. X., Lee, Tau Hong, Lin, Ray J. H., Ng, Lisa F. P., Ren, Ee Chee, Lin, Raymond T. P., Wang, Lin-Fa, Renia, Laurent, Lye, David Chien, Young, Barnaby E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201789/
https://www.ncbi.nlm.nih.gov/pubmed/35710572
http://dx.doi.org/10.1186/s13063-022-06345-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201789/
https://www.ncbi.nlm.nih.gov/pubmed/35710572
http://dx.doi.org/10.1186/s13063-022-06345-2

Ejemplares similares